Which has better valuation & earnings, FBRX or ORKA?

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forte Biosciences N/A N/A -$69.38M -$4.65 N/A Oruka Therapeutics N/A N/A -$105.43M -$2.03 N/A

Is FBRX or ORKA more profitable?

Oruka Therapeutics' return on equity of -21.65% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -94.82% -77.68% Oruka Therapeutics N/A -21.65% -20.88%

Which has better earnings & valuation, COGT or FBRX?

Forte Biosciences is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.16 N/A Forte Biosciences N/A N/A -$69.38M -$4.65 N/A

Is COGT or FBRX more profitable?

Cogent Biosciences' return on equity of -84.47% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -84.47% -47.72% Forte Biosciences N/A -94.82% -77.68%

Forte Biosciences (FBRX) Competitors

$76.99 0.00 (0.00%)

As of 08/27/2026

Compare

FBRX vs. CGON, MIRM, ORKA, TVTX, and COGT

Should you buy Forte Biosciences stock or one of its competitors? Forte Biosciences's main competitors and comparable companies include CG Oncology (CGON), Mirum Pharmaceuticals (MIRM), Oruka Therapeutics (ORKA), Travere Therapeutics (TVTX), and Cogent Biosciences (COGT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Forte Biosciences compare to CG Oncology?

Forte Biosciences (NASDAQ:FBRX) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Forte Biosciences has higher earnings, but lower revenue than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A
CG Oncology	$4.04M	1,637.21	-$160.99M	-$2.69	N/A

Forte Biosciences has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-94.82%	-77.68%
CG Oncology	-3,602.68%	-25.20%	-23.98%

77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by company insiders. Comparatively, 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, CG Oncology had 7 more articles in the media than Forte Biosciences. MarketBeat recorded 7 mentions for CG Oncology and 0 mentions for Forte Biosciences. CG Oncology's average media sentiment score of 0.82 beat Forte Biosciences' score of 0.00 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Forte Biosciences	Neutral
CG Oncology	Positive

Forte Biosciences currently has a consensus price target of $71.67, indicating a potential downside of 6.91%. CG Oncology has a consensus price target of $87.78, indicating a potential upside of 17.63%. Given CG Oncology's stronger consensus rating and higher possible upside, analysts clearly believe CG Oncology is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Forte Biosciences has a beta of 2.62, indicating that its share price is 162% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

Summary

CG Oncology beats Forte Biosciences on 10 of the 15 factors compared between the two stocks.

How does Forte Biosciences compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Forte Biosciences (NASDAQ:FBRX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Mirum Pharmaceuticals has higher revenue and earnings than Forte Biosciences. Forte Biosciences is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.44	-$23.36M	-$14.55	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A

77.6% of Forte Biosciences shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Mirum Pharmaceuticals has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.62, indicating that its share price is 162% more volatile than the broader market.

Forte Biosciences has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Mirum Pharmaceuticals' return on equity of -36.28% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Forte Biosciences	N/A	-94.82%	-77.68%

Mirum Pharmaceuticals presently has a consensus price target of $137.31, indicating a potential upside of 49.53%. Forte Biosciences has a consensus price target of $71.67, indicating a potential downside of 6.91%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Mirum Pharmaceuticals had 8 more articles in the media than Forte Biosciences. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 0 mentions for Forte Biosciences. Mirum Pharmaceuticals' average media sentiment score of 0.62 beat Forte Biosciences' score of 0.00 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Mirum Pharmaceuticals	Positive
Forte Biosciences	Neutral

Summary

Mirum Pharmaceuticals beats Forte Biosciences on 12 of the 16 factors compared between the two stocks.

How does Forte Biosciences compare to Oruka Therapeutics?

Forte Biosciences (NASDAQ:FBRX) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Forte Biosciences has a beta of 2.62, indicating that its share price is 162% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, indicating that its share price is 134% less volatile than the broader market.

Oruka Therapeutics' return on equity of -21.65% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-94.82%	-77.68%
Oruka Therapeutics	N/A	-21.65%	-20.88%

In the previous week, Oruka Therapeutics had 15 more articles in the media than Forte Biosciences. MarketBeat recorded 15 mentions for Oruka Therapeutics and 0 mentions for Forte Biosciences. Oruka Therapeutics' average media sentiment score of 0.26 beat Forte Biosciences' score of 0.00 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Forte Biosciences	Neutral
Oruka Therapeutics	Neutral

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Forte Biosciences currently has a consensus price target of $71.67, suggesting a potential downside of 6.91%. Oruka Therapeutics has a consensus price target of $133.00, suggesting a potential upside of 40.06%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Oruka Therapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

Oruka Therapeutics beats Forte Biosciences on 9 of the 13 factors compared between the two stocks.

How does Forte Biosciences compare to Travere Therapeutics?

Forte Biosciences (NASDAQ:FBRX) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Forte Biosciences has a beta of 2.62, suggesting that its stock price is 162% more volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Forte Biosciences has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. Travere Therapeutics' return on equity of -55.15% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-94.82%	-77.68%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

In the previous week, Travere Therapeutics had 37 more articles in the media than Forte Biosciences. MarketBeat recorded 37 mentions for Travere Therapeutics and 0 mentions for Forte Biosciences. Travere Therapeutics' average media sentiment score of 0.25 beat Forte Biosciences' score of 0.00 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Forte Biosciences	Neutral
Travere Therapeutics	Neutral

Forte Biosciences currently has a consensus price target of $71.67, suggesting a potential downside of 6.91%. Travere Therapeutics has a consensus price target of $68.00, suggesting a potential upside of 8.35%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Travere Therapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

77.6% of Forte Biosciences shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by insiders. Comparatively, 4.4% of Travere Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Travere Therapeutics has higher revenue and earnings than Forte Biosciences. Travere Therapeutics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A
Travere Therapeutics	$490.73M	12.06	-$25.55M	-$0.46	N/A

Summary

Travere Therapeutics beats Forte Biosciences on 11 of the 15 factors compared between the two stocks.

How does Forte Biosciences compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Forte Biosciences (NASDAQ:FBRX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

In the previous week, Cogent Biosciences had 8 more articles in the media than Forte Biosciences. MarketBeat recorded 8 mentions for Cogent Biosciences and 0 mentions for Forte Biosciences. Cogent Biosciences' average media sentiment score of 0.24 beat Forte Biosciences' score of 0.00 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cogent Biosciences	Neutral
Forte Biosciences	Neutral

Cogent Biosciences' return on equity of -84.47% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
Forte Biosciences	N/A	-94.82%	-77.68%

Cogent Biosciences has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.62, meaning that its stock price is 162% more volatile than the broader market.

77.6% of Forte Biosciences shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Forte Biosciences is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A

Cogent Biosciences currently has a consensus target price of $51.56, indicating a potential upside of 63.67%. Forte Biosciences has a consensus target price of $71.67, indicating a potential downside of 6.91%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cogent Biosciences is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cogent Biosciences beats Forte Biosciences on 11 of the 14 factors compared between the two stocks.

Get Forte Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBRX vs. The Competition

Export

Metric	Forte Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.63B	$3.91B	$7.25B	$13.13B
Dividend Yield	N/A	3.65%	2.57%	12.94%
P/E Ratio	-16.56	14.08	273.81	25.39
Price / Sales	N/A	1,407.75	692.78	114.04
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	8.89	15.45	10.45	6.33
Net Income	-$69.38M	-$22.78M	$3.48B	$358.24M
7 Day Performance	N/A	-1.22%	0.88%	1.17%
1 Month Performance	0.12%	-4.44%	-1.59%	-2.59%
1 Year Performance	469.87%	37.78%	18.08%	5.97%

Forte Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBRX Forte Biosciences	0.97 of 5 stars	$76.99 flat	$71.67 -6.9%	N/A	$1.63B	N/A	N/A	5
CGON CG Oncology	2.8536 of 5 stars	$73.40 -1.7%	$87.78 +19.6%	+92.2%	$6.51B	$4.04M	N/A	61
MIRM Mirum Pharmaceuticals	3.0447 of 5 stars	$99.53 -1.4%	$137.31 +38.0%	+21.9%	$6.46B	$521.31M	N/A	140
ORKA Oruka Therapeutics	3.4543 of 5 stars	$94.31 +1.9%	$133.00 +41.0%	+472.7%	$6.24B	N/A	N/A	N/A	Insider Trade
TVTX Travere Therapeutics	1.6019 of 5 stars	$66.07 +1.2%	$61.67 -6.7%	+159.4%	$6.23B	$490.73M	N/A	460	Trending News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBRX) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Forte Biosciences (FBRX) Competitors

FBRX vs. CGON, MIRM, ORKA, TVTX, and COGT

How does Forte Biosciences compare to CG Oncology?

Summary

How does Forte Biosciences compare to Mirum Pharmaceuticals?

Summary

How does Forte Biosciences compare to Oruka Therapeutics?

Summary

How does Forte Biosciences compare to Travere Therapeutics?

Summary

How does Forte Biosciences compare to Cogent Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBRX vs. The Competition

Forte Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Forte Biosciences (FBRX) Competitors

FBRX vs. CGON, MIRM, ORKA, TVTX, and COGT

How does Forte Biosciences compare to CG Oncology?

Which has better valuation & earnings, FBRX or CGON?

Is FBRX or CGON more profitable?

Do institutionals & insiders have more ownership in FBRX or CGON?

Does the media favor FBRX or CGON?

Do analysts recommend FBRX or CGON?

Which has more volatility & risk, FBRX or CGON?

Summary

How does Forte Biosciences compare to Mirum Pharmaceuticals?

Which has preferable valuation and earnings, MIRM or FBRX?

Do institutionals and insiders believe in MIRM or FBRX?

Which has more volatility & risk, MIRM or FBRX?

Is MIRM or FBRX more profitable?

Do analysts rate MIRM or FBRX?

Does the media refer more to MIRM or FBRX?

Summary

How does Forte Biosciences compare to Oruka Therapeutics?

Which has more volatility & risk, FBRX or ORKA?

Is FBRX or ORKA more profitable?

Does the media favor FBRX or ORKA?

Which has better valuation & earnings, FBRX or ORKA?

Do insiders & institutionals hold more shares of FBRX or ORKA?

Do analysts prefer FBRX or ORKA?

Summary

How does Forte Biosciences compare to Travere Therapeutics?

Which has more volatility & risk, FBRX or TVTX?

Is FBRX or TVTX more profitable?

Does the media favor FBRX or TVTX?

Do analysts recommend FBRX or TVTX?

Do insiders and institutionals hold more shares of FBRX or TVTX?

Which has better valuation and earnings, FBRX or TVTX?

Summary

How does Forte Biosciences compare to Cogent Biosciences?

Does the media refer more to COGT or FBRX?

Is COGT or FBRX more profitable?

Which has more risk and volatility, COGT or FBRX?

Do insiders & institutionals have more ownership in COGT or FBRX?

Which has better earnings & valuation, COGT or FBRX?

Do analysts recommend COGT or FBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBRX vs. The Competition

Forte Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools